Does Rallies show Form 4 insider transactions for ICCC?

Yes. Rallies tracks ICCC insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ICCC research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ICCC. It does not provide personalized investment advice.

ICCC (Immucell Corp) Stock Analysis - Insider Trades

Immucell Corp (ICCC) is a publicly traded Healthcare sector company. As of May 21, 2026, ICCC trades at $9.88 with a market cap of $89.65M and a P/E ratio of -140.91. ICCC moved -4.90% today. Year to date, ICCC is +63.31%; over the trailing twelve months it is +78.34%. Its 52-week range spans $3.38 to $10.25. Rallies surfaces ICCC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ICCC stock inside the company?

Recent ICCC insider activity includes te Boekhorst Paul Francis Olivier bought 2.43K, te Boekhorst Paul Francis Olivier bought 3.60K, te Boekhorst Paul Francis Olivier bought 2.56K, te Boekhorst Paul Francis Olivier bought 3.52K, and te Boekhorst Paul Francis Olivier bought 3.71K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ICCC Key Metrics

Key financial metrics for ICCC
Metric	Value
Price	$9.88
Market Cap	$89.65M
P/E Ratio	-140.91
EPS	$-0.07
Dividend Yield	0.00%
52-Week High	$10.25
52-Week Low	$3.38
Volume	0
Avg Volume	0
Revenue (TTM)	$29.93M
Net Income	$-545.40K
Gross Margin	42.59%

Recent ICCC Insider Trades

te Boekhorst Paul Francis Olivier bought 2.43K (~$13.38K) on Dec 4, 2025.
te Boekhorst Paul Francis Olivier bought 3.60K (~$18.15K) on Dec 3, 2025.
te Boekhorst Paul Francis Olivier bought 2.56K (~$12.79K) on Dec 3, 2025.
te Boekhorst Paul Francis Olivier bought 3.52K (~$17.75K) on Dec 3, 2025.
te Boekhorst Paul Francis Olivier bought 3.71K (~$18.05K) on Dec 2, 2025.

Latest ICCC News

ImmuCell reports $10.4M Q1 sales, net income up 34% to $1.9M — May 16, 2026
ImmuCell Q1 Sales Rise 28.4% to $10.4M, Tri-Shield® Up 38.5% — Apr 8, 2026
ImmuCell Corp Margin Rises to 41% as Net Loss Narrows to $1M — Mar 7, 2026
ImmuCell 2025 Sales Up 4.3% to $27.6M with $1.6M Operating Income — Mar 4, 2026
ImmuCell Q4 Sales Dip 1.6% to $7.6M, Takes $2.9M Re-Tain® Charge — Jan 9, 2026

ICCC Analyst Consensus

ICCC analyst coverage data. Average price target: $0.00.

Common questions about ICCC

Who is trading ICCC stock inside the company?: Recent ICCC insider activity includes te Boekhorst Paul Francis Olivier bought 2.43K, te Boekhorst Paul Francis Olivier bought 3.60K, te Boekhorst Paul Francis Olivier bought 2.56K, te Boekhorst Paul Francis Olivier bought 3.52K, and te Boekhorst Paul Francis Olivier bought 3.71K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ICCC?: Yes. Rallies tracks ICCC insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ICCC research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ICCC. It does not provide personalized investment advice.